Platinum-Triggered Bond-Cleavage of Pentynoyl Amide and N-Propargyl Handles for Drug-Activation

Abstract

The ability to create ways to control drug activation at specific tissues while sparing healthy tissues remains a major challenge. The administration of exogenous target-specific triggers offers the potential for traceless release of active drugs on tumor sites from antibody−drug conjugates (ADCs) and caged prodrugs. We have developed a metal-mediated bond-cleavage reaction that uses platinum complexes [K 2 PtCl 4 or Cisplatin (CisPt)] for drug activation. Key to the success of the reaction is a water-promoted activation process that triggers the reactivity of the platinum complexes. Under these conditions, the decaging of pentynoyl tertiary amides and N-propargyls occurs rapidly in aqueous systems. In cells, the protected analogues of cytotoxic drugs 5fluorouracil (5-FU) and monomethyl auristatin E (MMAE) are partially activated by nontoxic amounts of platinum salts. Additionally, a noninternalizing ADC built with a pentynoyl traceless linker that features a tertiary amide protected MMAE was also decaged in the presence of platinum salts for extracellular drug release in cancer cells. Finally, CisPt-mediated prodrug activation of a propargyl derivative of 5-FU was shown in a colorectal zebrafish xenograft model that led to significant reductions in tumor size. Overall, our results reveal a new metal-based cleavable reaction that expands the application of platinum complexes beyond those in catalysis and cancer therapy.

Using Ligand-Accelerated Catalysis to Repurpose Fluorogenic Reactions for Platinum or Copper

“…During the review process, a biocompatible platinum-catalyzed bond cleavage 76 and ligand effects on a palladium-based fluorescent probe for carbon monoxide have been published. 77 …”

Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status

“…The induction of apoptosis has been described as a surrogate of treatment response preceding changes in tumor size-acting as an early monitor of tumor response-and thus allowing for shorter assays that can be easily included in the clinical decision-making time regarding treatment selection [58,59]. Thus, we anticipate that if the assay were to be extended, the tumor size effect would emerge, as we recently observed in other studies [60].…”

Site-selective modification strategies in antibody–drug conjugates

“…7D), 97 carbonylacrylic reagents ( Fig. 7E), 98,99 and N-alkyl vinylpyridine salts (Fig. 7F) 100 and have been used to synthesise ADCs.…”